Division of Nephrology, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
JAMA Netw Open. 2021 Mar 1;4(3):e210775. doi: 10.1001/jamanetworkopen.2021.0775.
Ibuprofen is widely used in children worldwide, especially in those with cancer, fever, or trauma. However, large and high-quality studies of the association between ibuprofen and acute kidney injury (AKI) in children have been lacking.
To examine the association between the use of ibuprofen and the risk of hospital-acquired AKI in hospitalized children in China.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed the cohort of the Epidemiology of AKI in Chinese Hospitalized Patients (EACH) study, a large, multicenter retrospective study of 3 044 023 patients who were admitted to 1 of 25 academic medical centers in China between January 1, 2013, and December 31, 2015. Patient-level data were obtained from the electronic health record system of the participating centers. Hospitalized children aged 1 month to 18 years who had prescriptions and a certain number of serum creatinine (SCr) tests were included. Children with end-stage renal disease, community-acquired AKI, low baseline SCr level (<10 μmol/L), high standardized baseline SCr level (>4 times the sex- and age-specific reference value), or missing diagnosis code were excluded. Data analysis was conducted from January 1, 2020, to August 30, 2020.
Exposure to ibuprofen was coded as a time-dependent dichotomous variable.
Baseline SCr level was calculated for each patient as the mean of all available SCr values between the 30 days prior to admission and the first SCr testing within the first 3 days of hospitalization. Acute kidney injury was defined as an increase in SCr level of 26.5 μmol/L or higher within 48 hours or by 50% or more over the baseline value, according to the Kidney Disease: Improving Global Outcomes guidelines.
Among the 50 420 children (mean [SD] age, 5.0 [5.2] years; 30 640 boys [60.8%]) included in this study, 5526 (11.0%) used ibuprofen and 3476 (6.9%) developed hospital-acquired AKI during hospitalization. Ibuprofen use was associated with a statistically significantly increased risk of hospital-acquired AKI (hazard ratio [HR], 1.23; 95% CI, 1.14-1.34) after adjusting for confounders. Ibuprofen use was associated with a greater hazard in children who had chronic kidney disease vs those without (HR, 2.31 [95% CI, 1.73-3.10] vs 1.19 [95% CI, 1.09-1.29]), required intensive care vs those without this need (HR, 1.47 [95% CI, 1.24-1.75] vs 1.18 [95% CI, 1.07-1.29]), or were older vs younger (>10 years and >1 year to 10 years vs 1 month to 1 year) (HR, 1.64 [95% CI, 1.32-2.05]; 1.36 [95% CI, 1.23-1.52] vs 0.99 [95% CI, 0.86-1.13]). Dose-response analysis suggested that the association of ibuprofen with the risk of hospital-acquired AKI was dose-dependent.
This study found that ibuprofen was widely used and associated with an increased risk of hospital-acquired AKI in hospitalized children in China. The judicious use of ibuprofen and close monitoring of kidney function in children are needed.
布洛芬在全球范围内广泛用于儿童,尤其是癌症、发热或创伤患儿。然而,目前缺乏关于布洛芬与儿童急性肾损伤(AKI)之间关联的大型、高质量研究。
研究中国住院患儿中使用布洛芬与医院获得性 AKI 风险之间的关系。
设计、地点和参与者:这项队列研究分析了中国住院患者 AKI 流行病学研究(EACH)的队列,这是一项针对 25 家学术医疗中心 3044023 名患者的大型、多中心回顾性研究,这些患者于 2013 年 1 月 1 日至 2015 年 12 月 31 日期间入住中国的其中一家中心。患者水平的数据来自参与中心的电子健康记录系统。纳入了年龄在 1 个月至 18 岁之间、有处方和一定数量血清肌酐(SCr)检测的住院患儿。排除了终末期肾病、社区获得性 AKI、基线 SCr 水平较低(<10 μmol/L)、标准化基线 SCr 水平较高(>4 倍性别和年龄特异性参考值)或缺失诊断代码的患儿。数据分析于 2020 年 1 月 1 日至 2020 年 8 月 30 日进行。
将布洛芬暴露编码为一个时间依赖性的二分类变量。
为每个患者计算基线 SCr 水平,方法是将入院前 30 天内所有可用的 SCr 值的平均值与入院后前 3 天内首次 SCr 检测值进行平均。根据肾脏病:改善全球结局指南,急性肾损伤定义为在 48 小时内 SCr 水平升高 26.5 μmol/L 或以上,或与基线值相比升高 50%或以上。
在这项研究中,纳入了 50420 名(平均[标准差]年龄为 5.0[5.2]岁;30640 名男性[60.8%])患儿,其中 5526 名(11.0%)使用了布洛芬,3476 名(6.9%)在住院期间发生了医院获得性 AKI。在调整混杂因素后,布洛芬的使用与医院获得性 AKI 的风险显著增加相关(危险比[HR],1.23;95%CI,1.14-1.34)。与无慢性肾脏病的患儿相比,有慢性肾脏病的患儿(HR,2.31[95%CI,1.73-3.10] vs 1.19[95%CI,1.09-1.29])、需要重症监护的患儿(HR,1.47[95%CI,1.24-1.75] vs 1.18[95%CI,1.07-1.29])或年龄较大的患儿(>10 岁和>1 年至 10 岁与 1 个月至 1 岁)(HR,1.64[95%CI,1.32-2.05];1.36[95%CI,1.23-1.52] vs 0.99[95%CI,0.86-1.13])与医院获得性 AKI 的风险增加相关。剂量反应分析提示,布洛芬与医院获得性 AKI 风险之间的关联具有剂量依赖性。
这项研究发现,布洛芬在中国住院患儿中广泛使用,且与医院获得性 AKI 风险增加相关。需要谨慎使用布洛芬,并密切监测儿童的肾功能。